Answers are grounded in this paper and cite their sources.
Deep receptor scanning revealed temp-sensitive gpcrs that improve surface expression with pharmacochaperones, suggesting new therapeutic mechanisms.
G-protein coupled receptors (GPCRs) are a major class of therapeutic targets. These therapeutics include different classes of modulators, such as agonists and antagonists. A newer class of compounds, called pharmacochaperones, binds to the native conformation of a protein and stabilizes this conformation in the ensemble. Proper proteostasis of a specific protein can be restored by taking advantage of the thermodynamic stability that occurs from the connection between ligand binding and protein folding. Expression of proteins below normal physiological temperatures of 37°C can shift the ensemble’s thermodynamic equilibrium toward the native conformation. Interactions between residues would be less likely to be broken at a lower temperature, which preserves the tertiary structure. The native conformation is more stable and avoids degradation. The protein is trafficked to its preferred expression locale for subsequent function. Lowering the physiological temperature and the binding of pharmacochaperones individually increase preference to the native conformation of a protein by providing thermodynamic stability to unstable protein ensembles. We used this premise to find clinically relevant compounds that act as pharmacochaperones. To identify receptors that are sensitive to temperature, our lab developed a deep receptor scanning platform to measure the expression of 946 GPCRs and their response to a decrease in physiological temperature. Our results found a subset of GPCRs with increased surface expression when exposed to lower physiological temperatures. These results were cross-referenced with GPCRs that interact with clinically relevant compounds. A subset of these GPCRs were selected and exposed to small molecules for surface expression measurements. Our findings showcase some of these drugs act not only as modulators but also as pharmacological chaperones. This demonstrates that therapeutics act through multiple mechanisms and could direct us toward identifying features of pharmacochaperones through the expansion of this class of compounds.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: